Updating obesity management strategies: an audit of Italian specialists
- PMID: 35579858
- PMCID: PMC9556338
- DOI: 10.1007/s40519-022-01402-w
Updating obesity management strategies: an audit of Italian specialists
Abstract
Obesity negatively affects physical and psychological health and increases health care costs. Although there is increasing interest in early diagnosis and timely intervention, there are several principles of care included in the current guidelines for clinical management of obesity that can potentially be updated and improved to address the "clinical inertia" and, consequently, to optimize the management of adult obesity. Using an online Delphi-based process, an Italian board of experts involved in the management of obesity discussed the usefulness of a pro-active approach to the care of patients with obesity, providing a consensus document with practical indications to identify risk factors for morbidity and death and raise awareness throughout the treatment continuum, including the early stages of the disease. In clinical practice, it seems inappropriate to delay an intervention that could avoid progression to a more severe level of obesity and/or prevent the onset of obesity-related comorbidities.Level of evidence Level V, report of expert committee.
Keywords: Adipose tissue; Adult obesity; Bariatric surgery; Cardio-metabolic risk; Obesity comorbidities; Obesity management.
© 2022. The Author(s).
Conflict of interest statement
LB reports Advisory Boards: Novo Nordisk. Speaker: Bruno Farmaceutici and Therasience; FG reports Advisory Boards: AstraZeneca; Eli Lilly; Novo Nordisk; Roche Diabetes Care, Sanofi. Consultant: Boehringer Ingelheim; Lifescan; Merck Sharp & Dohme; Sanofi, AstraZeneca, Medimmune, Roche Diabetes Care, Sanofi, Medtronic. Research support: Eli Lilly, Roche Diabetes Care; FS has worked as a consultant, participated in studies, and/or received travel funds from the following companies, which are involved with obesity and related diseases: AstraZeneca, Aegerion Pharmaceuticals, Fujirebio, Pfizer, Amryt, BioItalia, Bruno farmaceutici, Damor pharmaceuticals and Novo Nordisk, GM reports Roche Diagnostici. The remaining authors have no competing interests to declare that are relevant to the content of this article.
References
-
- NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642. doi: 10.1016/S0140-6736(17)32129-3. - DOI - PMC - PubMed
-
- Mongraw-Chaffin ML, Peters SAE, Huxley RR, Woodward M. The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1.2 million participants. Lancet Diabetes Endocrinol. 2015;3:437–449. doi: 10.1016/S2213-8587(15)00086-8. - DOI - PMC - PubMed
-
- Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten LJ. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156. doi: 10.1136/bmj.i2156. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources